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The Screening and Management of Comorbid Depression in Type 1 Diabetes for Improved Compliance

INTRODUCTION
Advanced practice and primary care providers are increasingly managing the ever‐
growing population of patients with diabetes—with a 2016 American Academy of Family
Physicians (AAFP) study from the Medical Expenditures Panel Survey (MEPS) finding that a full
48 percent of medical encounters for the subset of patients with diabetes but no other chronic
health conditions were in fact managed by general clinicians.1 Patients with diabetes face
chronic, severe sequelae of their disease, often suffering comorbid conditions as well, including
mental health diagnoses. Physician assistants (PAs) are likely to face increased diabetic patient
caseloads—frequently including patients with unmet mental healthcare needs, and a review of
the current literature on management is warranted in order to optimize care.
Clinicians are typically familiar with the general course and management of the more
prevalent type 2 diabetes. Type 1 diabetes, specifically, is an autoimmune condition typically
diagnosed in childhood and which, unlike some forms and stages of type 2 diabetes, requires
immediate and lifelong insulin therapy, with use of lancets, meters, and injections of insulin
every few hours. Diet and exercise are first line preventative treatments for new onset type 2
diabetes, and oral medications can then be initiated to stall progression to insulin‐dependent
type 2 in general practice. Type 1 diabetics, however, typically do not have clinically actionable
preventative therapeutic and lifestyle modification windows. Although autoimmune cascade‐
halting preventative drug target studies are promising,2,3,4 they are currently in the nascent
stages of development, and no current diet nor oral medication reliably prevents type 1 in
humans. For these reasons, clinicians in both endocrinology specialties and in the primary care
setting need data on best practice guidelines as well as to be apprised of known comorbidities
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their patients are likely to face, from what is an unpreventable diagnosis in the case of type 1,
and often a difficult to prevent diagnosis in type 2.
HIGH RATE OF DIABETIC KETOACIDOSIS IN YOUNG DIABETICS
Due to the nature of their autoimmune destruction of beta cells of Langerhans, type 1
diabetics are prone to rapid diabetic ketoacidosis (DKA) decompensation, especially with poor
insulin management. Foster’s 2019 management and outcomes comparison of type 1 registry
patient characteristics from two cohorts between 2016‐2018 and 2010‐2012 shed light on the
most common age range for DKA events requiring overnight hospitalization in that population,
namely adolescents and young adults, and child patients with poor glycemic control and
depression leads to more emergency room visits. Not without precedent, the study also found
that between the ages of 15‐18, patient metabolic control worsened to the point that average
Hgba1c for that age group averaged 9.3% (78 mmol/mol). These patients were also at a
heightened risk of experiencing ketoacidosis in the three months prior. This study’s probands
were found to have a marked risk of DKA in teenagers and young adults.5,9 Tellingly, patients
with higher average Hgba1c levels are at an increased risk for DKA (P<0.001). 5
HIGH RATE OF CARDIOVASCULAR COMPLICATIONS IN TYPE 1
Complications of diabetes are frequent in both type 1 and type 2 diabetes – even in
children and teens. A 2017 observational study by colleagues of the Colorado School of Public
Health’s Department of Epidemiology between 2002‐2015 across five sites of type 1 and type 2
diabetic patients diagnosed younger than age 20 found significant complications in even young
patients. Type 1 patients were shown to have high rates of cardiovascular complications found
by sphygmoCor‐Vx pulse wave velocity, demonstrating arterial stiffness. The same patients also
3
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exhibited heightened risk of blood pressures equal or greater to the 95th%ile by age (<18).
Further, patients had poor glucose control, as shown by an average Hgba1c of 9.2 (5.7%
normal).6 Patients frequently struggle to maintain healthy glucose control, whether type 1 or
type 2, but type 1 patients do not have struggling pancreatic function to fall back on and can
almost immediately decompensate. Further care to optimize dosing is necessary for both sets
of patients.
COMORBIDITY OF DEPRESSED MOOD OR MAJOR DEPRESSIVE DISORDER (MDD) IN TYPE 1
A recent 2019 Danish clinic questionnaire combined with medical records analysis for
the purpose of evaluating quality of life, found complications of diabetes associated strongly
with depressed mood. The researchers used the status of ever having an upper limb soft tissue
diabetic lesion (using color photographs in case patients were unfamiliar with the medical
terminology for their dermopathy) and found higher risk of depressed mood (P<0.01) in that
subset. The WHO‐Five Well‐being Index (WHO‐5) is a Danish‐developed scale with greater
scores pointing toward best possible quality of life based on positive mood, restful sleep,
activity, and general interest in one’s future. WHO‐5 scores below or equal to 50 indicate a high
risk of stress or depression. In the questionnaire study, duration of diabetes, BMI, blood
pressure, HbA1c, urinary albumin to creatinine ratio (UACR), and vibration perception threshold
(VPT) were all measured, and quality of life WHO‐5 scores in all patients with at least one such
lesion were significantly lower. This data demonstrates the mood burden of diabetic sequelae.7
Another commonly utilized option is the Beck Triad of Depression Inventory, assessing patient
beliefs about their own value, the fairness of the world, and the potential for the future to be
better than today. Clinicians will typically find most useful the metric developed by Drs. Spitzer,
4
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Williams, and Kroenke’s: Patient Health Questionnaire‐9 (PHQ‐9) or the abbreviated form of
which (PHQ‐2). PHQ‐2 asks the patient to reflect on the last two weeks and to state if 1) they
have had little interest or pleasure in doing things and 2) if they have found themselves feeling
down, depressed, or hopeless.
A separate King’s College of London 2017 study examining data from the 1958 British birth
cohort of over 8000 subjects showed a bidirectional relationship between autoimmune disorder
and depression. Importantly, the retrospective paper found this association held true
independent of genetic risk of depression in these individuals. Likewise, depression was found to
increase the subsequent hazard of developing an autoimmune disorder, (P = 0.0095). This may
point to additive genetic risk previously unaccounted for in genome wide association studies
(GWAS).8,13,14,15 Common environmental exposures, baseline inflammation levels, and behaviors
common to one which influence development of the other (e.g. depression leading to low
exercise and vitamin D deficiency or diabetes leading to high inflammation, social withdrawal,
etc) may explain the strong linkage as more data emerges. The 1958 data originally come from
the cohort of all individuals born during one week in 1958 in Scotland, England, and Wales, using
self‐report data from age 33, age 42, and age 46, their genotype data of 2002‐2004, from which
polygenic risk scores for depression were generated for each individual. Due to the multiple
collection points of the data over the years, the study was uniquely able to support a bidirectional
relationship.8 In addition to autoimmune comorbidity, studies have shown that the burden of
poorly‐controlled and mood‐based compliance with regimen lead to adverse outcomes. History
of diagnosed depression, diabetes‐related distress, and depressed mood were associated with a
higher rate of microvascular complications. Diagnosed depression and diabetes‐related distress
5
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also showed higher HbA1c at baseline when insulin was initiated. Insulin therapy improved
glycemic control, while preexisting depressed mood declined and diabetes‐related distress
remained unchanged. 7, 10, 13, 14, 19
TREATMENT MODALITIES: CONCOMITANT TALK THERAPY
Of the 21% of respondents in the 2019 Danish study who were diagnosed with
depression, 52% had been given counseling therapy by primary care, 55% counseling with a
psychiatrist, and 62% had been prescribed antidepressant medication. WHO‐5 scores for this
subgroup were also assessed, resulting in lower quality of life score. The patients in this survey
were more likely (40% versus 16%) to score <50 on the WHO‐5 if they had ever been diagnosed
with depression (P<0.001). This Danish cohort who responded had better average glucose
control than average diabetic patients, but unfortunately, rates of depression even in this self‐
responding, better‐compliance group were two‐to three‐times higher among T1D patients than
the general population, consistent with previous findings in the literature.7
TREATMENT MODALITIES: CHOICE OF SSRI (BLACK BOX WARNING FOR CHILDREN AND TEENS)
Various studies have examined the use of Selective Serotonin Reuptake Inhibitors SSRI
and other antidepressant medications in the case of autoimmune disease and specifically
diabetes. A 2012 study in northern India over the course of 12 months followed 40 adult
patients in outpatient endocrinology with Hba1c >7% were assigned to SSRI treatment. Fasting,
postprandial, and Hba1c%, and then all patients were maintained on their current diabetic
medication while also being prescribed 10 mg/day of escitalopram, although without a sham
study arm. Patients were maintained or increased on their dose until they achieved control of
depression symptoms. This Gehlawat, et al. study found better glycemic control with the use of
6
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SSRI, specifically escitalopram. Unfortunately, a les common HAM‐D depression scoring system
was used, so the results are not easily compared across studies. However, static dose and
titrating dose arms of the study showed a significant difference in depression outcomes (p
<0.001).9 Similarly, an Alvar 2017 meta‐analysis and guideline review for nurse practitioners
utilized antidepressant fluoxetine, sertraline, or escitalopram to treat comorbid depression in
diabetics.10 The review recommended compliance with the American Academy of Pediatrics
(AAP) suggestion of annual screening for depressive symptoms beginning at age 11, unless
patients of their families present with worrisome symptoms or complains earlier. 10,9
Previously, an older 2011 Markowitz, et al. metanalysis of depression treatment in
diabetes and outcomes found mixed success and reporting methods of glycemic control in talk
therapy—generally cognitive behavioral therapy (CBT)—and SSRI treated probands. One of the
reviewed double‐blind random controlled trails had a fairly robust cohort (n=351) of both type
1 and type 2 diabetics, and used sertraline intervention after Beck Depression Inventory (BDI),
showing 42% of patients on the regimen achieved remission of depression symptoms.11
Unfortunately, screening methodologies and outcome measures were not equivalent between
the various studies, so comparisons across studies are currently difficult to substantiate. 11, 10
Thought positive effects on mood and diabetic management have been found, clinicians
must also consider the pharmacokinetics and pharmacodynamics of the SSRIs themselves.
Common side effects of SSRIs include typical gastrointestinal complaints. In children and
teenagers, there are black box warnings for volitional effects such as increased risk for suicidal
ideation or attempt when initiating treatment, necessitating close follow up and stabilization. 10
Typically, SSRIs are dose dependent for sexual dysfunction (especially sertraline when
7
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increasing 100 to 150). Fluoxetine, sertraline, and escitalopram are frequently used in studies
due to their relatively low side effects and length of time on the market. Citalopram may not be
an ideal antidepressant in this population as its use is correlated with excessive weight gain and
the AAFP and FDA have cautioned on its use in patients with risks for torsades de pointes,
though follow up studies have failed to replicate QT prolongation risk. Escitalopram has been
shown to cause fewer sexual side effects than other anti‐depressants and may benefit patients
with intimacy concerns, especially as diabetics are a population with increased risk of erectile
dysfunction.12, 16, 17, 18
MEDICATION AND FOLLOW UP
Especially when treating minors, psychiatric referral, therapy referral, family support,
and good clinical follow up are vital. Weekly visits and close management are ideal. 10, 13, 16

Drug. Lower age
limit, starting
dosage

Fluoxetine (>8
years old,
initiate 5 mg
anticipatory
guidance GI
upset and black
box warning
with return 1
month,

Sertraline (>6
years old,
initiate 12.5 mg
anticipatory
guidance GI
upset and black
box warning
with return 1
month,

Escitalopram
(>12 years old,
initiate 5 mg
anticipatory
guidance GI
upset and black
box warning
with return 1
month,

Titration and
Therapeutic
Target Dosage

titrate by 5 mg,
target dose 10‐
20 mg at least
12 months,

titrate by 25 mg,
target dose 50‐
100 mg at least
12 months,

titrate by 5 mg,
target dose 10‐
20 mg at least
12 months,
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Maximum Dose
and Cessation

max dose 40 mg,
2 months to
taper off entire
class)

max dose 200
mg, 2 months to
taper off entire
class),

Supportive
studies

Alvar meta‐
Alvar meta‐
Alvar meta‐
analysis NP 2017 analysis NP 2017 analysis NP 2017
Lexi‐Comp, inc

Lexi‐Comp, inc

max dose 20 mg,
2 months to
taper off entire
class)

Lexi‐Comp, inc

Gehlawat 2013
CONCLUSION
In summation, the current literature points to the necessity and efficacy of primary care
providers managing diabetic depression as a means of treating the whole person and though is
corroborated generally by small sample sizes, shows great promise in both glucoregulation and
improved quality of life. Gaps in the literature such as the plausibility of common autoimmune
mechanism and long term outcomes of treatment would best be resolved by establishing larger
cohorts of patients on talk therapy regimens or SSRI therapy in order to have larger, more
generalizable groups to study, ideally with beneficial outcomes for individual patients. Clinicians
still know little about long term SSRI effects in depressed diabetics. Also, the autoimmune
cascade is understood, but causal or correlational mechanisms with mood have not been fully
elicited. It will also be important to examine targeted treatments towards avolition (e.g.
escitalopram) aspects of depression versus anhedonia (e.g. sertraline) targets. Further studies
may also look at the ideal length of treatment and separate talk therapy from diabetes
management skills training or study the two combined. Future studies on these parameters
after the implementation of depression management in type 1 diabetes will present important
clinical data for best practice.
9

The Screening and Management of Comorbid Depression in Type 1 Diabetes for Improved Compliance

In conclusion, PAs should prioritize SSRI, talk therapy, or preferably a combination of the
two for all type 1 diabetic patients under their care until quality of life measures, depression
screening goals, compliance, and Hgba1c levels are maintained. Caution must be taken with the
initiation of all SSRIs, especially in minors, who must be followed closely as well as have a
parent or guardian onboard for warning signs of rare though serious black box SSRI initiation
outcomes in minors (i.e. increased goal‐directed behavior in the context of suicidal ideation). 10
Drawbacks in application also include the necessity of managing potential tapering of
medication or the transfer to psychiatric management.

SUMMARY OF ACTIONABLE OUTCOMES TABLE
SCREENING: PHQ‐2 In the past 2 weeks, have you 1) had little interest or pleasure in doing
things? and 2) felt down, depressed, or hopeless?
TREATMENT INITIATION: 1) Talk therapy initiation of weekly and then bimonthly meetings
with a therapist
2) If age 12 or older, initiate escitalopram. If ages 6‐12, initiate sertraline. In minors stress
blackbox warning of suicidality potential and follow up immediately and frequently. Continue
medications for a minimum of 12 months.
EVALUATION OF DIABETIC AND DEPRESSION OUTCOMES: Focus on patient experience,
Hgba1c goals, quality of life WHO‐5, re‐evaluation of PHQ‐2.
TAPERING OF DEPRESSION CARE OR TRANSFER TO OVERSIGHT BY PSYCH: Discuss with
patient and/or parents the efficacy of outcomes and take 2 months minimum to taper off
medications.
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